Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 17, Issue 3, Pages 319-326Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458510388824
Keywords
benign; multiple sclerosis; disability; MRI; multicentre
Categories
Funding
- Teva Pharmaceutical Industries Ltd.
- Biogen-Dompe AG
- Italian MS Society
- Bayer Schering Pharma
- Merck Serono SA
- sanofi-aventis
- AstraZeneca
- Genentech, Inc.
- Novartis
- Biogen Idec
- Active Biotech
- European Charcot Foundation
- Lundbeck Inc.
- Talecris Biotherapeutics
- Roche
- UCB
- Wyeth
- MediciNova, Inc.
- Merck Serono
- GlaxoSmithKline
- NIH
- NIHR UCLH Comprehensive Biomedical Research Centre
- MS Society of Great Britain
- MS Society of Northern Ireland
- Teva Pharmaceutical Industries Ltd
- Almirall
- Eli Lilly and Company
- Genzyme Corporation
- Fundacio Esclerosi Multiple (FEM)
- Actelion Pharmaceuticals Ltd.
- Antisense Therapeutics Limited
- European Community (EEC)
- Dutch Multiple Sclerosis Society
- Genmab A/S
- Fondazione Italiana Sclerosi Multipla
- Fondazione Mariani
Ask authors/readers for more resources
Background and Objectives: We evaluated clinical and conventional MRI features of a large population of patients with non-disabling MS to identify potential markers of a benign disease course. Methods: In seven MAGNIMS centres we retrospectively identified 182 patients with benign (B) MS (EDSS score <= 3.0, disease duration >= 15 years) and 187 patients with non-disabling relapsing-remitting MS (NDRRMS) (Expanded Disability Status Scale score >= 3.0, disease duration between 5 and 14 years), in whom clinical data were collected within two weeks from a brain T2-weighted scan. Brain T2 lesion volume (LV) was measured in all patients. In 146 BMS and 146 NDRRMS patients, clinical data were also available after a median follow up of 29 months (range: 7-104 months). Results: Mean LV was higher in BMS than in NDRRMS patients (p < 0.001), but the mean ratio between LV and disease duration was higher in NDRRMS than in BMS patients (1.1 vs. 0.6 ml/year, p < 0.001). In BMS patients, brain LV was correlated with EDSS score increase at follow up (r=0.18, p=0.03). Conclusions: An overall low rate of brain LV increase during a long-lasting disease course might be a feature of BMS. In BMS patients, a high brain LV might be associated with worsening of locomotor disability at short-term follow up.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available